Zentalis Pharmaceuticals, Inc.(ZNTL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Zentalis Pharmaceuticals, Inc. (ZNTL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZNTL at 11.6/100 on a 32-signal composite quality model, placing it at rank #2,719 of 2,777 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (1.8) and profitability (2.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Zentalis Pharmaceuticals, Inc. reports net income of $-42.3M, free cash flow of $-37.2M. Top institutional holders of ZNTL by reported 13-F value include 5AM Venture Management, BlackRock, Squadron Capital Management, based on the most recent SEC filings. ZNTL trades on the Nasdaq exchange and files with the SEC under CIK 1725160. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZNTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zentalis Pharmaceuticals, Inc. directly from SEC EDGAR.